FDA — authorised 22 November 2024
- Application: NDA216540
- Marketing authorisation holder: BRIDGEBIO PHARMA
- Local brand name: ATTRUBY
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Attruby in United States
FDA authorised Attruby on 22 November 2024
Marketing authorisations
FDA
- Marketing authorisation holder: BRIDGEBIO PHARMA
- Status: approved
Attruby in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in United States
Frequently asked questions
Is Attruby approved in United States?
Yes. FDA authorised it on 22 November 2024; FDA has authorised it.
Who is the marketing authorisation holder for Attruby in United States?
BRIDGEBIO PHARMA holds the US marketing authorisation.